REGENXBIO Reports Third Quarter 2021 Financial Results and O

/PRNewswire/ -- Announced eye care collaboration with AbbVie to develop and commercialize RGX-314 AbbVie and REGENXBIO form a strategic partnership combining...

Related Keywords

Rockville , Maryland , United States , American , David Rosen , Brendan Burns , Tricia Truehart , Technology Platform , Technology Platform Licensees , Nasdaq , Novartis , Development Expenses , Pivotal Program , Technology Licensees , Technology Products , Drug Administration , American Academy Of Ophthalmology , Exchange Commission , Technology Licensee Program , Healthcare Royalty Management , Pathway Development Consortium , Corporate Communications , Solid Biosciences Inc , Medicines Partnership Bespoke Gene Therapy Consortium , Securities Exchange , Chief Executive Officer , Care Collaboration , Mediated Antibody , American Academy , New Orleans , Hereditary Angioedema , Rare Genetic , Investigational New Drug , Mucopolysaccharidosis Type , Good Manufacturing Practice , Manufacturing Facility , Licensee Program , Administrative Expenses , Platform Licensees , Securities Act , Securities Exchange Act , Financial Condition , Novartis Gene , Tax Benefit , Comprehensive Income , Regenxbio Inc ,